Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H25N |
Molecular Weight | 243.3871 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCN(CC1)C2(CCCCC2)C3=CC=CC=C3
InChI
InChIKey=JTJMJGYZQZDUJJ-UHFFFAOYSA-N
InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2
Phencyclidine is an illegal, hallucinogenic drug that was initially used as an anesthetic agent in the 1950s and early 1960s, but was then withdrawn in 1965 because of dissociative hallucinogenic effects that were often disturbing and sometimes severe and prolonged. Phencyclidine is a noncompetitive NMDA (N-methyl-D-aspartate) receptor antagonist and glutamate receptor antagonist, but also interacts with other receptor sites, and may have effects with dopamine, opioid and nicotinic receptors. Phencyclidine disrupts the functioning of receptors for the neurotransmitter glutamate, which plays a major role in the perception of pain as well as in learning, memory, and emotion. It also influences the actions of the neurotransmitter dopamine, which causes the euphoria associated with drug use. Phencyclidine overdose deaths may occur after taking a large dose, though many phencyclidine related deaths result from delusions and other psychological consequences of the drug’s use. There have been reports of death due to accidental drowning, leaping from high places, and motor vehicle accidents in addition to violent episodes of self-mutilation, suicides, and homicides.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine. | 2000 Jun 15 |
|
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. | 2001 |
|
Amaurosis fugax associated with phencyclidine inhalation. | 2001 |
|
Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment. | 2001 |
|
Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats. | 2001 |
|
Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. | 2001 Apr |
|
Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain. | 2001 Apr |
|
M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. | 2001 Apr 13 |
|
Elucidating the role of muscarinic receptors in psychosis. | 2001 Apr 27 |
|
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. | 2001 Aug |
|
Neurotransmitters and apoptosis in the developing brain. | 2001 Aug 15 |
|
There are disadvantages, too, for oral fluid, on-site urine testing. | 2001 Dec |
|
Uncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex. | 2001 Feb |
|
The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. | 2001 Feb |
|
A conformational intermediate between the resting and desensitized states of the nicotinic acetylcholine receptor. | 2001 Feb 16 |
|
Effects of a novel, selective, sigma1-ligand, MS-377, on phencyclidine-induced behaviour. | 2001 Jul |
|
Blockade of the central generator of locomotor rhythm by noncompetitive NMDA receptor antagonists in Drosophila larvae. | 2001 Jul |
|
Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules. | 2001 Jun |
|
Psychotogenic properties of benzodiazepine receptor inverse agonists. | 2001 Jun |
|
Advances in schizophrenia. | 2001 Jun |
|
Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43. | 2001 Jun |
|
Site-specific charge interactions of alpha-conotoxin MI with the nicotinic acetylcholine receptor. | 2001 Jun 29 |
|
Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. | 2001 Mar |
|
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. | 2001 Mar |
|
The effects of phencyclidine pretreatment on cocaine-mediated hepatotoxicity in mice. | 2001 May 1 |
|
Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission. | 2001 Nov |
|
Effects of ketamine in normal and schizophrenic volunteers. | 2001 Oct |
|
Drug contamination of US paper currency. | 2001 Oct 1 |
|
Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. | 2001 Oct 5 |
|
Differential effects of delta 9-THC on spatial reference and working memory in mice. | 2001 Sep |
|
Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
|
MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. | 2001 Sep 21 |
|
Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. | 2001 Summer |
|
Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. | 2002 |
|
Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. | 2002 |
|
Glutamatergic mechanisms in schizophrenia. | 2002 |
|
Substance abuse monitoring by the Correctional Service of Canada. | 2002 Feb |
|
Effect of MS-153 on the development of behavioral sensitization to stereotypy-inducing effect of phencyclidine. | 2002 Feb 1 |
|
Drug discrimination under concurrent variable-ratio variable-ratio schedules. | 2002 Jan |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
||
|
DEA NO. |
7471
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C738
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
PHENCYCLIDINE
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
D010622
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
8058
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
6468
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
6472
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
m8603
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID6023446
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
Phencyclidine
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
1058
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
DB03575
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
SUB09755MIG
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
100000085809
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
77-10-1
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL275528
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
J1DOI7UV76
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
2121
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)